Company: MIRM
Filing Date: 2025-08-12
Form Type: S-3ASR
Source: 0001193125-25-178937
Chunk: 17

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-3ASR
Chunk 17
---
 of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our common stock and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have no current plans to issue any shares of preferred stock. Additional Series of Preferred Stock We will incorporate by reference as an exhibit to the registration statement, which includes this prospectus, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering. This description and the applicable prospectus supplement (or any related free writing prospectus that we may authorize to be provided to you) will include:

| • |     | the title and stated value; |

| • |     | the number of shares authorized; |

| • |     | the liquidation preference per share; |

| • |     | the purchase price; |

| • |     | the dividend rate, period and payment date, and method of calculation for dividends; |

| • |     | whether dividends will be cumulative or non-cumulative and, if 
 cumulative, the date from which dividends will accumulate;     |

| • |     | the procedures for any auction and remarketing, if any; |

| • |     | the provisions for a sinking fund, if any; |

| • |     | the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those 
 redemption and repurchase rights;                                                                                 |

| • |     | any listing of the preferred stock on any securities exchange or market; |

| • |     | whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, 
 or how it will be calculated, and the conversion period;                                                         |

| • |     | whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or 
 how it will be calculated, and the exchange period;                                                               |

| • |     | voting rights, if any, of the preferred stock; |

12

| • |     | preemptive rights, if any; |

| • |     | restrictions on transfer, sale or other assignment, if any; |

| • |     | whether interests in the preferred stock will be represented by depositary shares; |

| • |     | a discussion of any material United States federal income tax considerations applicable to the preferred stock; |

| • |     | the relative ranking and preferences of the preferred stock as to dividend rights